Target intelligence / Profile preview

TBC1 domain family member 2B (TBC1D2B)

Target
TBC1D2B
Molecular classification
Enzyme, GTPase activating protein (specifically, RAB-specific GTPase-activating protein), Other
01

Overview

TBC1 domain family member 2B (TBC1D2B) is a RAB-specific GTPase-activating protein within the Tre2-Bub2-Cdc16 (TBC) domain-containing superfamily. It interacts principally with RAB5, RAB7, RAB22, and RAB31, key regulators of endosomal and lysosomal trafficking and membrane vesicle dynamics. TBC1D2B is important for the sorting and recycling of membrane proteins, in part through modulating endocytosis and stabilization of E-cadherin at cell junctions, and thus impacts processes such as cell-cell adhesion, epithelial-mesenchymal transition, cell invasion, and metastasis. Germline bi-allelic loss-of-function mutations in TBC1D2B cause a progressive neurodevelopmental disorder with neurologic decline, seizures, gingival overgrowth, and jaw anomalies. In cancer biology, TBC1D2B acts as a negative regulator of invasion and metastasis, partly through suppression of Rab22-induced E-cadherin internalization. There are currently no known drugs that target TBC1D2B, and its role is primarily as a molecular regulator rather than a direct therapeutic target.

Other names
KIAA1055NEDSGOTBC1D2b
02

Biological functions

Regulator of RAB GTPases (RAB5, RAB7, RAB22, RAB31), involved in endosomal membrane traffickingRegulation of endocytosis and recycling of epithelial junction proteins such as E-cadherinPositive regulation of autophagyNegative regulator of cell migration, invasion, and epithelial-mesenchymal transition
03

Disease associations

Progressive neurological disorder with developmental delay and neurodegenerationGingival fibromatosis (gum overgrowth)Cherubism and abnormal mandible morphologyPotential tumor suppressor role (inhibits cancer invasion and metastasis)
04

Safety considerations

Loss-of-function associated with severe, progressive, early-onset neurodegenerative disease with epileptic seizures, intellectual disability, and progressive neurobehavioral declineDeficiency associated with gingival overgrowth and facial bone abnormalities

Beyond the preview

Go deeper on TBC1 domain family member 2B (TBC1D2B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TBC1 domain family member 2B (TBC1D2B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call